United Therapeutics reports Q1 EPS $6.63, consensus $6.28

Reports Q1 revenue $794.4M, consensus $726.36M. “2025 is off to a tremendous start as we reported yet another quarter of record revenue,” said CEO Martine Rothblatt. “Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we’ll progress our innovation and revolution waves of growth with the readout of TETON 2 in idiopathic pulmonary fibrosis and the planned commencement of our UKidney first in human clinical study, respectively. Moreover, we’re excited to advance our multiple shots on goal approach to creating an unlimited supply of transplantable organ alternatives with anticipated filings of investigational new drug applications with the FDA for our UHeart and UThymoKidney products.” COO Michael Benkowitz added, “This quarter’s record revenue performance reflects the diligent efforts and strategic focus of our commercial team as we continue to expand our reach and solidify our position in the pulmonary hypertension marketplace as the prostacyclin products of choice. We look forward to building on this performance for the remainder of the year.”